📊 ANGO Key Takeaways
Is Angiodynamics Inc. (ANGO) a Good Investment?
AngioDynamics faces significant operational headwinds with negative operating income (-10.8% margin) and negative free cash flow (-$12.4M) despite a healthy gross margin of 55.8%, indicating execution and cost management issues. While the balance sheet remains solid with zero long-term debt and adequate liquidity (2.24x current ratio), the company is burning cash operationally and showing revenue contraction (-3.8% YoY), suggesting structural challenges in the medical device market. The modest improvement in net income YoY (+81.6%) is insufficient to offset deteriorating profitability trends and negative cash generation.
AngioDynamics shows mixed fundamentals: the balance sheet is clean with no long-term debt, solid liquidity, and a healthy gross margin, which provides flexibility while the business restructures. However, revenue is still declining, operating losses remain meaningful, and both operating cash flow and free cash flow are negative, so the improvement in net loss alone is not yet enough to support a more bullish view.
Why Buy Angiodynamics Inc. Stock? ANGO Key Strengths
- Strong gross margin of 55.8% indicates competitive pricing power and product quality
- Conservative balance sheet with zero long-term debt and $41.6M cash provides financial flexibility
- Healthy liquidity position with 2.24x current ratio and 1.33x quick ratio
- Improved net loss YoY (+81.6%) suggests some operational progress or one-time items
- Strong balance sheet with $41.64M in cash, no long-term debt, and positive equity of $176.33M
- Healthy gross margin of 55.8%, indicating the core product mix still carries solid underlying economics
- Liquidity remains adequate with a 2.24x current ratio and 1.33x quick ratio, reducing near-term financial stress
ANGO Stock Risks: Angiodynamics Inc. Investment Risks
- Negative operating cash flow of -$11.3M indicates company is burning cash despite positive gross profit
- Revenue decline of 3.8% YoY combined with negative operating margins suggests demand weakness or market share loss
- Negative free cash flow of -$12.4M is unsustainable and will deplete cash reserves if trend continues
- Operating losses with -10.8% operating margin indicate inability to convert gross profits to operating profits
- No insider buying activity in last 90 days may reflect management concerns about near-term prospects
- Revenue declined 3.8% YoY, raising concern about demand durability and growth quality
- Operating margin of -10.8% and net margin of -11.1% show the company is still not sustainably profitable
- Negative operating cash flow and free cash flow indicate profits have not yet converted into cash generation
Key Metrics to Watch
- Operating cash flow trend - must return to positive to validate business model sustainability
- Revenue growth trajectory - need to stabilize declining top-line to assess market competitiveness
- Operating margin improvement - critical to reach profitability as cost structure appears misaligned with revenue base
- Free cash flow generation - key indicator of whether company can self-fund operations and R&D
- Gross margin stability - monitor if pricing power is maintained amid competitive pressures
- Revenue growth by product category and overall operating margin improvement
- Operating cash flow and free cash flow trend toward sustained breakeven or positive generation
Angiodynamics Inc. (ANGO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.24x current ratio provides a solid financial cushion.
ANGO Profit Margin, ROE & Profitability Analysis
ANGO vs Healthcare Sector: How Angiodynamics Inc. Compares
How Angiodynamics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Angiodynamics Inc. Stock Overvalued? ANGO Valuation Analysis 2026
Based on fundamental analysis, Angiodynamics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Angiodynamics Inc. Balance Sheet: ANGO Debt, Cash & Liquidity
ANGO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Angiodynamics Inc.'s revenue has shown modest growth of 7% over the 5-year period. The most recent EPS of $-1.33 indicates the company is currently unprofitable.
ANGO Revenue Growth, EPS Growth & YoY Performance
ANGO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $72.0M | -$4.4M | $-0.11 |
| Q2 2026 | $72.8M | -$6.4M | $-0.15 |
| Q1 2026 | $67.5M | -$10.9M | $-0.26 |
| Q3 2025 | $72.0M | -$4.4M | $-0.11 |
| Q2 2025 | $72.8M | -$10.7M | $-0.26 |
| Q1 2025 | $67.5M | -$12.8M | $-0.31 |
| Q3 2024 | $75.2M | -$8.5M | $-0.24 |
| Q2 2024 | $79.1M | -$8.5M | $-0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Angiodynamics Inc. Dividends, Buybacks & Capital Allocation
ANGO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Angiodynamics Inc. (CIK: 0001275187)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ANGO
What is the AI rating for ANGO?
Angiodynamics Inc. (ANGO) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ANGO's key strengths?
Claude: Strong gross margin of 55.8% indicates competitive pricing power and product quality. Conservative balance sheet with zero long-term debt and $41.6M cash provides financial flexibility. ChatGPT: Strong balance sheet with $41.64M in cash, no long-term debt, and positive equity of $176.33M. Healthy gross margin of 55.8%, indicating the core product mix still carries solid underlying economics.
What are the risks of investing in ANGO?
Claude: Negative operating cash flow of -$11.3M indicates company is burning cash despite positive gross profit. Revenue decline of 3.8% YoY combined with negative operating margins suggests demand weakness or market share loss. ChatGPT: Revenue declined 3.8% YoY, raising concern about demand durability and growth quality. Operating margin of -10.8% and net margin of -11.1% show the company is still not sustainably profitable.
What is ANGO's revenue and growth?
Angiodynamics Inc. reported revenue of $155.1M.
Does ANGO pay dividends?
Angiodynamics Inc. does not currently pay dividends.
Where can I find ANGO SEC filings?
Official SEC filings for Angiodynamics Inc. (CIK: 0001275187) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ANGO's EPS?
Angiodynamics Inc. has a diluted EPS of $-0.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ANGO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Angiodynamics Inc. has a SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ANGO stock overvalued or undervalued?
Valuation metrics for ANGO: ROE of -9.8% (sector avg: 15%), net margin of -11.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ANGO stock in 2026?
Our dual AI analysis gives Angiodynamics Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ANGO's free cash flow?
Angiodynamics Inc.'s operating cash flow is $-11.3M, with capital expenditures of $1.2M. FCF margin is -8.0%.
How does ANGO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -11.1% (avg: 12%), ROE -9.8% (avg: 15%), current ratio 2.24 (avg: 2).